Sakar Healthcare Ltd (SAKAR) is currently trading at 944.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Sakar Healthcare Limited manufactures pharmaceutical formulations and oncology products, operating conventional dosage-form facilities alongside an oncology-focused API, formulation, and CDMO platform. Its products include injectables, liquid orals, tablets, capsules, dry powders, lyophilized injections, and oncology cytotoxic APIs supplied to domestic and international customers. The company delivered strong first-half FY27 operating momentum, with revenue rising 45% and EBITDA increasing 90% year-on-year. EBITDA margin expanded from 22% to 28%, while profit after tax grew 134%, reflecting improving oncology mix, operating leverage, and stronger contribution from higher-value activities. Oncology has become the central growth engine, contributing approximately INR50 crore of quarterly revenue and nearly half of the business. Management expects oncology to exceed 60% of revenue within two to three years, supported by registrations, site transfers, exports, CDMO projects, and commercialization of approved products. Sakar has created a substantial regulatory and commercialization pipeline, including 351 dossiers shared globally, 191 regulatory submissions, 22 marketing authorizations, 36 European filings, and 33 site variations. However, the revenue opportunity remains dependent on approval timing, tender cycles, artwork completion, and the gradual launch of authorized products. Backward integration is becoming strategically important: Sakar has developed 21 oncology APIs, with eight products commercialized and two CEP applications approved. Management expects greater captive API consumption over time to reduce input-cost volatility and potentially lift oncology EBITDA margins from approximately 30% toward 34–35% over several years.

Over the past 52 weeks, Sakar Healthcare Ltd has traded between a low of ₹352.50 and a high of ₹1,229.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Sakar Healthcare Ltd has a market capitalization of approximately 2,079.14. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Sakar Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 48.51 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 2,079.14 Cr, Sakar Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Sakar Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Sakar Healthcare Ltd is 48.51. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Sakar reported revenue from operations of Rs 87.42 crore in Q2 FY27. This was 51.9% higher than Rs 57.56 crore reported in Q2 FY26.

Revenue from operations for the quarter ended September 30, 2026 (Q2 FY27) was ₹87.4161 crore, as reported in the results statement.